
Dr Tolaney on the Clinical Implications of First-Line T-DXd Plus Pertuzumab in HER2+ Breast Cancer
“Seeing that T-DXd and pertuzumab are, in essence, doubling progression-free survival and almost doubling the complete response rate compared with THP, it does mean that this hopefully will become a new standard of care option for our patients.” Sara M. …